Noxilizer Closes $30M Round as EtO Era Fades in Europe

Noxilizer's $30M raise accelerates NO2 sterilization as Europe tightens EtO rules and demand for safer alternatives grows

8 Apr 2026

Noxilizer, a US-based developer of nitrogen dioxide sterilisation technology, has closed a $30m growth capital round led by NewVale Capital to expand commercial access to its platform globally.

The raise comes as regulatory pressure on ethylene oxide, the dominant sterilisation method for medical devices, intensifies on both sides of the Atlantic. The US Environmental Protection Agency's 2024 rule requires a 90% reduction in EtO emissions from commercial sterilisers, with compliance deadlines stretching to 2028. In Europe, tightening restrictions under the REACH chemicals regulation are pushing manufacturers toward alternatives.

EtO sterilises an estimated 20 billion medical devices annually in the US alone. Finding a viable substitute at that scale is not straightforward.

Noxilizer's NO2 platform has regulatory authorisation from both the FDA and the European Medicines Agency. The technology operates at low temperatures, between 10 and 30 degrees Celsius, leaves no carcinogenic residuals, and delivers cycle times of three to six hours. That combination makes it particularly suited to heat-sensitive biologics, prefilled syringes, and polymer-based assemblies that cannot tolerate conventional sterilisation conditions.

Global demand for NO2 sterilisation is forecast to grow at more than 10% annually through 2036, reaching close to $1.8bn. The UK, Germany, and France are identified as among the fastest-growing European markets, with low-temperature device sterilisation accounting for roughly 34% of NO2 application demand in 2026.

The broader context is one of compressed timelines and rising complexity. As medical devices incorporate more sensitive biological components, the sterilisation methods developed for simpler products are becoming harder to justify on both safety and regulatory grounds.

Whether NO2 can scale quickly enough to absorb meaningful volumes of EtO-dependent manufacturing remains an open question. Validation processes are lengthy, and switching sterilisation methods carries its own regulatory burden for device makers already stretched by compliance demands elsewhere.